Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 170, Issue 11, Pages 1153-1157Publisher
AMER THORACIC SOC
DOI: 10.1164/rccm.200404-533OC
Keywords
airway wall alterations; allergic asthma; immunostimulatory DNA sequence oligonucleoticles; nonhuman primate
Categories
Funding
- NCRR NIH HHS [P51 RR000169, RR00169] Funding Source: Medline
- NIAID NIH HHS [AI40628] Funding Source: Medline
- NIEHS NIH HHS [P01 ES000628, ES05707, P30 ES005707, F32 ES005707, ES00628] Funding Source: Medline
Ask authors/readers for more resources
To determine whether inhaled immunostimulatory DNA sequence oligonucleotides containing CpG motifs mitigate the pathophysiologic manifestation of the asthmatic phenotype (airways hyperresponsiveness and airways remodeling), rhesus monkeys with experimentally induced allergic airways disease were treated seven times with inhaled immunostimulatory oligonucleotides (or sham) periodically for 33 weeks. Airways hyperresponsiveness was reduced twofold in immunostimulatory DNA sequence-treated compared with sham-treated monkeys. Airways from immunostimulatory oligonucleotide-treated monkeys had thinner reticular basement membranes, fewer mucous cells, fewer eosinophils, and fewer mast cells than sham-treated allergic monkeys. We conclude that inhaled immunostimulatory oligonucleotides can attenuate the magnitude of airway hyperreactivity and airways remodeling produced in nonhuman primates with experimentally induced allergic airways disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available